Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox

Login to Healthcare Professionals

If you are not registered yet, » register here.

» login

A Novel Group C Meningococcal Conjugate Vaccine

Conjugate vaccines represent a new generation of vaccines in which the body’s immune system elicits a stronger, longer lasting antibody response across a wider age range than non-conjugate vaccines. The novel group C meningococcal conjugate vaccine is composed of specific fragments of the meningococcal polysaccharide coat linked to a non-toxic tetanus toxoid. The end result is a higher level of protection against infectious diseases. This long-term protection in children enables conjugate vaccines to be used in routine child immunization programs.

The populations at risk from bacterial meningitis span all age categories from infants to adults but children from 3 months to 5 years of age and adolescents (15-18) are most susceptible. In Europe and North America, group C meningococcus is a leading cause of meningococcal infection, frequently resulting in permanent brain damage and death. In the United States, meningococcal C infections occur at an estimated rate of one to three cases out of 100,000 people each year -- primarily children and young adults -- with a fatality rate of approximately 15 %.

For any further information about novel group C meningococcal conjugate vaccines, please contact your physician.

 » Printversion

  » find


Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
» read more

Baxter receives preparedness contract from Austrian Ministry of Health for Pandemic Influenza Vaccine
» read more

Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
» read more

Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,